Navigation Links
U.S. District Court Rules in Favor of Lilly in Amylin Litigation
Date:6/8/2011

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a preliminary injunction that sought to impose restrictions on the Lilly Diabetes sales force and other relief. Amylin recently filed litigation involving the two companies' diabetes collaboration agreement.

"We are pleased with the Court's decision to vacate the temporary restraining order and deny Amylin's request for a preliminary injunction," said Robert A. Armitage, senior vice president and general counsel for Lilly "We have complied with our contractual obligations under our agreements with Amylin, and done so in a manner fully consistent with all applicable laws. We believe that Amylin's allegations against Lilly are entirely without merit and we fully expect to prevail in this litigation."

Enrique Conterno, president of Lilly Diabetes, said, "We are committed to offering a broad range of treatment options, including important new therapies, to people with diabetes and their health care providers. There is more work to be done, and we will continue to work hand in hand with all of our diabetes partners to achieve better outcomes for patients."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This press release contains forward-looking statements about our alliance with Amylin, and it reflects Lilly's current beliefs. There are substantial risks and uncertainties in the process of drug development and commercialization. Further, we cannot predict the outcome of any litigation with Amylin or its effect on our collaboration. For further discussion of risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
2. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
3. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
6. Sensipar® Patents Upheld By District Court
7. Winner Medical Honored with Shenzhen Baoan District Quality Award
8. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
9. German District Court Finds RENASYS™ GO NPWT System Non-infringing
10. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
11. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/12/2017)... , July 12, 2017 CarpalAID is a revolutionary new ... or surgery. Carpal tunnel syndrome affects more than 8 ... twice the rate of men. The common methods of treating CTS ... with uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn ...
(Date:7/11/2017)... WHIPPANY, N.J. , July 11, 2017  Bayer has ... across eight countries as part of its prestigious Bayer Hemophilia ... Children,s Hospital of Philadelphia and Uniformed ... are among the winners. Grant recipients were announced ... Thrombosis and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the launch of ... colleges and universities at the APPA 2017 Annual Conference and Exhibition in ... smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air ...
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit against Dr. ... ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In Gegham ... Ale claims on its bottle that it is made from real ginger. , When ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to regulate ... says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help ... on Monday, July 21st. , The kit uses colorful, engaging and educational illustrations ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... (ACL) offer patients improved quality of life five years after injury, according to ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five years ...
Breaking Medicine News(10 mins):